February 1, 2017 A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
February 1, 2017 Validity of the Symbol Digit Modalities Test as a Cognition Performance Outcome Measure for Multiple Sclerosis
January 31, 2017 Accelerating drug development for Alzheimer’s disease through the use of data standards
January 31, 2017 Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team
January 31, 2017 Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients
January 12, 2017 A Standardised Method for Interpreting the Association Between Mutations and Phenotypic Drug Resistance in Mycobacterium Tuberculosis
January 12, 2017 Patient-Reported Outcome (PRO) Consortium Translation Process: Consensus Development of Updated Best Practices
January 12, 2017 Emerging Good Practices for Translatability Assessment (TA) of Patient-Reported Outcome (PRO) Measures
January 5, 2017 Tuberculosis and Antimicrobial Resistance – New Models of Research and Development Needed
